Statin use in primary inflammatory breast cancer: A cohort study

T. M. Brewer, H. Masuda, D. D. Liu, Y. Shen, P. Liu, Takayuki Iwamoto, K. Kai, C. M. Barnett, W. A. Woodward, J. M. Reuben, P. Yang, G. N. Hortobagyi, N. T. Ueno

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background:Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied.Methods:We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin)). We used the Kaplan-Meier method to estimate the median progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS), and a Cox proportional hazards regression model to test the statistical significance of potential prognostic factors.Results:In the multivariable Cox model, H-statins were associated with significantly improved PFS compared with no statin (hazard ratio=0.49; 95% confidence interval=0.28-0.84; P

Original languageEnglish
Pages (from-to)318-324
Number of pages7
JournalBritish Journal of Cancer
Volume109
Issue number2
DOIs
Publication statusPublished - Jul 23 2013

Fingerprint

Inflammatory Breast Neoplasms
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cohort Studies
Proportional Hazards Models
Disease-Free Survival
Survival
Anti-Inflammatory Agents
Cholesterol

Keywords

  • hydrophilic
  • inflammatory breast cancer
  • lipophilic
  • overall survival
  • progression-free survival
  • statin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brewer, T. M., Masuda, H., Liu, D. D., Shen, Y., Liu, P., Iwamoto, T., ... Ueno, N. T. (2013). Statin use in primary inflammatory breast cancer: A cohort study. British Journal of Cancer, 109(2), 318-324. https://doi.org/10.1038/bjc.2013.342

Statin use in primary inflammatory breast cancer : A cohort study. / Brewer, T. M.; Masuda, H.; Liu, D. D.; Shen, Y.; Liu, P.; Iwamoto, Takayuki; Kai, K.; Barnett, C. M.; Woodward, W. A.; Reuben, J. M.; Yang, P.; Hortobagyi, G. N.; Ueno, N. T.

In: British Journal of Cancer, Vol. 109, No. 2, 23.07.2013, p. 318-324.

Research output: Contribution to journalArticle

Brewer, TM, Masuda, H, Liu, DD, Shen, Y, Liu, P, Iwamoto, T, Kai, K, Barnett, CM, Woodward, WA, Reuben, JM, Yang, P, Hortobagyi, GN & Ueno, NT 2013, 'Statin use in primary inflammatory breast cancer: A cohort study', British Journal of Cancer, vol. 109, no. 2, pp. 318-324. https://doi.org/10.1038/bjc.2013.342
Brewer, T. M. ; Masuda, H. ; Liu, D. D. ; Shen, Y. ; Liu, P. ; Iwamoto, Takayuki ; Kai, K. ; Barnett, C. M. ; Woodward, W. A. ; Reuben, J. M. ; Yang, P. ; Hortobagyi, G. N. ; Ueno, N. T. / Statin use in primary inflammatory breast cancer : A cohort study. In: British Journal of Cancer. 2013 ; Vol. 109, No. 2. pp. 318-324.
@article{7b76aea101b440149a0f92b12661ddde,
title = "Statin use in primary inflammatory breast cancer: A cohort study",
abstract = "Background:Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied.Methods:We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin)). We used the Kaplan-Meier method to estimate the median progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS), and a Cox proportional hazards regression model to test the statistical significance of potential prognostic factors.Results:In the multivariable Cox model, H-statins were associated with significantly improved PFS compared with no statin (hazard ratio=0.49; 95{\%} confidence interval=0.28-0.84; P",
keywords = "hydrophilic, inflammatory breast cancer, lipophilic, overall survival, progression-free survival, statin",
author = "Brewer, {T. M.} and H. Masuda and Liu, {D. D.} and Y. Shen and P. Liu and Takayuki Iwamoto and K. Kai and Barnett, {C. M.} and Woodward, {W. A.} and Reuben, {J. M.} and P. Yang and Hortobagyi, {G. N.} and Ueno, {N. T.}",
year = "2013",
month = "7",
day = "23",
doi = "10.1038/bjc.2013.342",
language = "English",
volume = "109",
pages = "318--324",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Statin use in primary inflammatory breast cancer

T2 - A cohort study

AU - Brewer, T. M.

AU - Masuda, H.

AU - Liu, D. D.

AU - Shen, Y.

AU - Liu, P.

AU - Iwamoto, Takayuki

AU - Kai, K.

AU - Barnett, C. M.

AU - Woodward, W. A.

AU - Reuben, J. M.

AU - Yang, P.

AU - Hortobagyi, G. N.

AU - Ueno, N. T.

PY - 2013/7/23

Y1 - 2013/7/23

N2 - Background:Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied.Methods:We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin)). We used the Kaplan-Meier method to estimate the median progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS), and a Cox proportional hazards regression model to test the statistical significance of potential prognostic factors.Results:In the multivariable Cox model, H-statins were associated with significantly improved PFS compared with no statin (hazard ratio=0.49; 95% confidence interval=0.28-0.84; P

AB - Background:Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied.Methods:We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin)). We used the Kaplan-Meier method to estimate the median progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS), and a Cox proportional hazards regression model to test the statistical significance of potential prognostic factors.Results:In the multivariable Cox model, H-statins were associated with significantly improved PFS compared with no statin (hazard ratio=0.49; 95% confidence interval=0.28-0.84; P

KW - hydrophilic

KW - inflammatory breast cancer

KW - lipophilic

KW - overall survival

KW - progression-free survival

KW - statin

UR - http://www.scopus.com/inward/record.url?scp=84881113396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881113396&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.342

DO - 10.1038/bjc.2013.342

M3 - Article

C2 - 23820253

AN - SCOPUS:84881113396

VL - 109

SP - 318

EP - 324

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -